Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis

BACKGROUND: Several studies have reported the incidence of immune-related adverse events (irAEs) as a predictor of the efficacy of anti-programmed cell death protein 1 antibodies in patients with cancer. However, immortal time bias has not always been fully addressed in these studies. In this retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawai, Taketo, Taguchi, Satoru, Nakagawa, Tohru, Kamei, Jun, Nakamura, Yu, Obinata, Daisuke, Yamaguchi, Kenya, Kaneko, Tomoyuki, Kakutani, Shigenori, Tokunaga, Mayuko, Uemura, Yukari, Sato, Yusuke, Enomoto, Yutaka, Nishimatsu, Hiroaki, Fujimura, Tetsuya, Fukuhara, Hiroshi, Takahashi, Satoru, Kume, Haruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883255/
https://www.ncbi.nlm.nih.gov/pubmed/35210308
http://dx.doi.org/10.1136/jitc-2021-003965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883255/
https://www.ncbi.nlm.nih.gov/pubmed/35210308
http://dx.doi.org/10.1136/jitc-2021-003965

Ejemplares similares